Publication at First Faculty of Medicine, Third Faculty of Medicine |
2014
Abstract
Dipeptidyl peptidase-4 inhibitors represent a newer class of antidiabetic drugs, which we use more in type 2 diabetes mellitus treatment. Recenty, there are several new information regarding their effects on immunity.
Partial immunosuppression was observed after their administration, maybe due to affecting chemotaxis and T lymphocyte migration. This immunosuppression can be accompanied on the one hand by adverse effects, such as increased frequency of infections, but on the other hand there are some ideas about utilization this knowledge for the treatment of autoimmune diseases.